HMNC Brain Health and Develco Pharma Announce Promising Preliminary Results in Treatment-Resistant Depression (TRD), suggesting antidepressant efficacy and showing Placebo-Level Dissociative Side Effects in Phase 2 oral prolonged-release Ketamine (KET01)
Retrieved on:
Thursday, March 31, 2022
University of Zurich, Company, University, Aggression, MDD, Social psychiatry, Analgesic, Clinical trial, Treatment-resistant depression, Human, Lists of diseases, PTSD, Addiction, Coronavirus Scientific Advisory Board (Turkey), Ketamine, SCOPE, Psychiatry, Workforce, Grammatical mood, Safety, TRD, Chrono, VC, COVID-19, GLOBE, CRO, Anxiety, Department, Depression, Biozentrum University of Basel, Panic disorder, Patient, Major depressive disorder, Partnership, Pharmaceutical industry, MADRS, Schizophrenia, Psychotherapy
Potential first-in-class oral prolonged-release formulation of ketamine, KET01, suggests larger improvement in Montgomery-sberg Depression Rating Scale (MADRS) scores at 15 days compared to placebo.
Key Points:
- Potential first-in-class oral prolonged-release formulation of ketamine, KET01, suggests larger improvement in Montgomery-sberg Depression Rating Scale (MADRS) scores at 15 days compared to placebo.
- Importantly, safety results from the trial demonstrated that KET01 was well tolerated, with no treatment-related serious adverse events reported.
- The Ketabon program, a joint venture between HMNC Brain Health and Develco Pharma in Switzerland comprises an oral prolonged-release formulation of ketamine for TRD with minimal dissociative side effects.
- Clinical development of oral prolonged-release ketamine could also be potentially expanded into other indications, such as anxiety, aggression, PTSD, and panic disorder.